# GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

> **NCT05335018** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 76 (estimated)

## Conditions studied

- Relapsed/refractory Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab, Poseltinib, Lenalidomide

## Key facts

- **NCT ID:** NCT05335018
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335018, "GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05335018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*